Berge K, Schirmer H, Øvrebotten T, Nahoui H, Gullestad L, Ingul CB, Hole T, Mo R, Larsby K, Norekvål TM, Omland T, Ørn S, Myhre PL (2025)
Improvements in medical therapy and prognosis for patients with HFrEF following the 2021 ESC HF guidelines
ESC Heart Fail (in press)
DOI 10.1002/ehf2.15337, PubMed 40574622

Holt MF, Michelsen AE, Flø A, Khan Y, Bjørnø VK, Skjelland M, Bjerkeli V, Paus B, Escobar Kvitting JP, Halvorsen B, Wien TN, Raki M, Gullestad L, Aukrust P, Broch K, Ueland T, Gude E (2025)
Hepatocyte Growth Factor: A Marker of Cardiac Function, Mortality, and Disease Subtype in Cardiac Amyloidosis
JACC Adv, 4 (6 Pt 1), 101828 (in press)
DOI 10.1016/j.jacadv.2025.101828, PubMed 40570404

Dahl TB, Quiles-Jiménez A, Broch K, Anstensrud AK, Gullestad L, Andersen GØ, Kleveland O, Øgaard J, Bjerkeli V, Rashidi A, Yang K, Holven KB, Aukrust P, Bjørås M, Huse C, Halvorsen B (2025)
The N-6 methyladenosine dynamics in STEMI and the effect of IL-6 inhibition - a hypothesis generating sub-study of the ASSAIL-MI trial
Front Immunol, 16, 1532325
DOI 10.3389/fimmu.2025.1532325, PubMed 40547027